MODERNA INC

Member Only Articles

AI Health Factor Performance Trends

Latest Insights

15 February, 2025
Moderna Faces Significant Stock Decline Amidst Competitive Biotech Landscape and Earnings Challenges
Read More >>
14 February, 2025
Moderna Faces Significant Stock Decline Amidst Competitive Biotech Landscape and Earnings Challenges
Moderna has been facing a tumultuous period in the stock market, with its shares plummeting nearly 24% in the past week alone, contributing to a staggering decline of around 59% over the last six mont...
Read More
12 February, 2025
Investors Remain Optimistic Despite Challenges as Moderna Targets Long-Term Growth with Innovative mRNA Pipeline
Recent trading activity shows that investors are presently bullish on Moderna, with 46% of trades reflecting positive expectations. The stock is valued at $37.38 but has seen a decline of 5.18%. Analy...
Read More
11 February, 2025
Investors Remain Optimistic Despite Challenges as Moderna Targets Long-Term Growth with Innovative mRNA Pipeline
Recent trading activity shows that investors are presently bullish on Moderna, with 46% of trades reflecting positive expectations. The stock is valued at $37.38 but has seen a decline of 5.18%. Analy...
Read More
10 February, 2025
Moderna Faces Declining Stock Performance Amidst Analyst Caution and Need for Diversification
Moderna, Inc. (NASDAQ: MRNA), a leading player in biotechnology specializing in mRNA therapeutics and vaccines, currently has a market cap of $15.9 billion. In an upcoming earnings report scheduled fo...
Read More

Most Read

Join Foliko Premium!

Unlock the entire library of Foliko's Generative AI Investment Research. Plus, get AI powered trading signals and stock price predictions.

Go Premium - 7 Day Free Trial

Any content provided on our website is for information purposes only. We do not provide investment advice, nor do we consider ourselves a financial institution. Seek a duly licensed professional for investment advice.